Lauren Panco

START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials

START enhances its global leadership by integrating Advarra’s advanced regulatory and technology solutions, creating a seamlessly connected site network to accelerate trials and relieve pressure on the oncology drug development ecosystem The START Center for Cancer Research (“START”), the leading global community-based early-phase oncology research network, today announced a strategic partnership with Advarra, the premier […]

START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials Read More »

START Launches Hope Hub to Connect Patients, Physicians, and Advocacy Groups to Community-Based Cancer Trials

The START Center for Cancer Research (“START”), the world’s largest early-phase community-based cancer trial site network, today announced the launch of the START Hope Hub, a powerful new digital patient and physician-focused platform that connects patients, caregivers, advocacy groups, and referring oncologists with quick access to START’s 720+ oncology clinical trials and informational resources. With

START Launches Hope Hub to Connect Patients, Physicians, and Advocacy Groups to Community-Based Cancer Trials Read More »

Sourcing Better PDX Models with a Streamlined “Clinic-to-Bench” Pipeline

Discover how XenoSTART’s clinic-to-bench pipeline delivers more clinically relevant PDX models, real-world patient data, and accelerated drug development. Patient-derived xenograft (PDX) models provide the most accurate way to mimic clinical tumor characteristics and behavior in preclinical studies. By directly transplanting tumor tissue from patients into immunodeficient hosts, resulting PDX models preserve the original human tumors’

Sourcing Better PDX Models with a Streamlined “Clinic-to-Bench” Pipeline Read More »